Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection
Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection
批准号:
9882940
负责人:
Gaya K. Amarasinghe
金额:
$79.64万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-03-01 至 2024-02-29
关键词:
AddressAffinityAfricaBindingBiochemicalBiochemistryBiological AssayBioterrorismCategory A pathogenCell physiologyCellsCollaborationsComplexCoupledCrystallizationDataData SetDemocratic Republic of the CongoDisease OutbreaksEbola virusEquilibriumFamily memberFilovirusFrankfurt-Marburg Syndrome VirusGene ExpressionGenesGenetic TranscriptionGenomeGoalsGrowthHealthHeterogeneous-Nuclear Ribonucleoprotein LHeterogeneous-Nuclear RibonucleoproteinsHumanInfectionIntegration Host FactorsJointsLigandsMediatingMessenger RNAMutateNational Institute of Allergy and Infectious DiseaseNatureNucleoproteinsPathogenicityPathway interactionsPeptidesPhosphorylationPlayPopulationPositioning AttributeProtein DephosphorylationProteinsProteomicsRNARNA BindingRNA VirusesRNA chemical synthesisRNA-Directed RNA PolymeraseReactionRecording of previous eventsRegulationRoleStructureSurfaceTertiary Protein StructureTestingTherapeuticTranscription InitiationTranscription Initiation SiteTranscriptional RegulationTransfectionUnited StatesViralViral GenesViral Hemorrhagic FeversViral ProteinsVirulenceVirusVirus DiseasesVirus ReplicationVirus-like particleWestern AfricaZoonosesbasegenomic RNAglobal healthinnovationinsightinterdisciplinary approachknock-downmultidisciplinarymutantnew therapeutic targetnoveloverexpressionpathogenprotein protein interactionstemsuccesstherapeutic developmenttherapy developmentubiquitin ligaseviral RNA
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
The filoviruses, Ebola and Marburg viruses (EBOV and MARV), are emerging, negative-strand RNA viruses
associated with outbreaks of severe viral hemorrhagic fever. The virulence and emerging nature of these
zoonotic pathogens makes them a significant threat to human health, potential agents of bioterrorism, and
NIAID category A priority pathogens. Currently, no approved anti-filovirus therapeutics are available.
Importantly, there is a major gap in our understanding with regard to the role of host factors at critical stages in
the viral replication cycle. The overall goal of this revised R01 application is to characterize EBOV VP30
(eVP30), a key viral protein that facilitates viral transcription, and its interactions with host factors. Our plan
builds on recent successes in structurally and functionally characterizing how eVP30 interacts with the viral
nucleoprotein (NP) to modulate EBOV RNA synthesis and on a joint (Amarasinghe, Basler, and Krogan
groups) unbiased proteomics screen using EBOV proteins as bait that uncovered 193 high-confidence EBOV-
human protein-protein interactions (PPIs), including one between eVP30 and the host ubiquitin ligase RBBP6.
A crystal structure of this complex revealed that RBBP6 and the viral NP compete for the same VP30 binding
surface. Comparison of NP and RBBP6 peptides that bind eVP30 revealed a common PPxPxY motif that is
necessary for the interaction. Whereas knockdown of endogenous RBBP6 stimulated viral transcription and
increased EBOV infectivity, overexpression of RBBP6 or its peptide severely inhibited EBOV transcription and
infection. Interestingly, at least two additional eVP30 interactors from our dataset (hnRNP L and hnRNP UL1)
also possess PPxPxY motifs. Based on these findings, we propose a multidisciplinary approach to (1)
Determine the structure of eVP30 N-terminus and define its association with RNA and protein ligands in the
absence and presence of NP; (2) Determine the mechanisms by which eVP30-interacting proteins RBBP6,
hnRNP L, and hnRNP UL1 modulate eVP30 function and RNA synthesis; and (3) Test the hypothesis that
eVP30 modulates the function of host factors RBBP6, hnRNP L, and hnRNP UL1. These studies will
characterize unique host interactions that negatively regulate EBOV replication with the goals of defining how
EBOV manipulates host pathways and identifying novel therapeutic targets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterizing the role of LDL related receptor 1 (Lrp1) as host entry factor for multiple bunyaviruses
-
批准号:10667857
-
项目类别:
-
资助金额:$78.36万
-
财政年份:2023
-
负责人:Gaya K. Amarasinghe
-
依托单位:
HSP90 paralog selective small molecules as anti-old-world alpha-viral therapeutic leads.
-
批准号:10753347
-
项目类别:
-
资助金额:$24.77万
-
财政年份:2023
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
-
批准号:10683329
-
项目类别:
-
资助金额:$27.21万
-
财政年份:2022
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
-
批准号:10481430
-
项目类别:
-
资助金额:$29.65万
-
财政年份:2022
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis
-
批准号:10375591
-
项目类别:
-
资助金额:$74.2万
-
财政年份:2021
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Development and characterization of engineered therapeutic antibodies against SARS-CoV-2
-
批准号:10865147
-
项目类别:
-
资助金额:$38.88万
-
财政年份:2021
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Development and characterization of engineered therapeutic antibodies against SARS-CoV-2
-
批准号:10458689
-
项目类别:
-
资助金额:$64.99万
-
财政年份:2021
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Development and characterization of engineered therapeutic antibodies against SARS-CoV-2
-
批准号:10669612
-
项目类别:
-
资助金额:$63.87万
-
财政年份:2021
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis
-
批准号:10573316
-
项目类别:
-
资助金额:$73.95万
-
财政年份:2021
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Development and characterization of engineered therapeutic antibodies against SARS-CoV-2
-
批准号:10240126
-
项目类别:
-
资助金额:$66.73万
-
财政年份:2021
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses
-
批准号:10081794
-
项目类别:
-
资助金额:$29.99万
-
财政年份:2020
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses
-
批准号:10211125
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2020
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection
-
批准号:9765490
-
项目类别:
-
资助金额:$83.27万
-
财政年份:2019
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection
-
批准号:10576914
-
项目类别:
-
资助金额:$76.21万
-
财政年份:2019
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection
-
批准号:10347335
-
项目类别:
-
资助金额:$77.43万
-
财政年份:2019
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection
-
批准号:10721290
-
项目类别:
-
资助金额:$6.12万
-
财政年份:2019
-
负责人:Gaya K. Amarasinghe
-
依托单位:
DEVELOPMENT, VALIDATION, AND OPTIMIZATION OF HTS SCREENS TARGETING NIPAH AND HENDRA VIRUS RNA SYNTHESIS
-
批准号:9470967
-
项目类别:
-
资助金额:$53.38万
-
财政年份:2017
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Molecular Mechanisms of Filoviral-host Interactions
-
批准号:10555051
-
项目类别:
-
资助金额:$335.5万
-
财政年份:2016
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Structural and Functional Characterization of the Ebola Virus Replication Complex
-
批准号:9312729
-
项目类别:
-
资助金额:$274.29万
-
财政年份:2016
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Administrative Core
-
批准号:10555052
-
项目类别:
-
资助金额:$27.52万
-
财政年份:2016
-
负责人:Gaya K. Amarasinghe
-
依托单位:
海外基金